# Five Decades of Pancreas Transplantation at the University Hospital of Zurich—A Story of Continuous Improvement and Success

**Authors:** Michael C. Frey, Sandro Hügli, Olivier de Rougemont, Kerstin Hübel, Thomas Schachtner, Elena Rho, Lukas Weidmann, Roger Lehmann, Jakob Nilsson, Lukas Frischknecht, José Oberholzer, Fabian Rössler

PMC · DOI: 10.1111/ctr.70368 · Clinical Transplantation · 2025-11-05

## TL;DR

This paper shows how pancreas transplant success rates improved significantly over 50 years at a Zurich hospital due to better surgical techniques and immunosuppression.

## Contribution

A 50-year retrospective analysis of pancreas transplantation outcomes at a single center, showing marked improvements in survival and insulin independence.

## Key findings

- Patient and graft survival rates improved significantly across five eras of surgical techniques.
- Insulin-free survival rates increased dramatically from Era 3 to Era 5.
- Advancements in surgery and immunosuppression made pancreas transplantation a safe and effective treatment.

## Abstract

Pancreas transplantation (PT) represents the gold standard in patients with type I diabetes mellitus (T1D) and end‐stage kidney disease (ESKD). We aimed to describe the evolution of PT at the University Hospital of Zurich from 1973 to 2023, and to analyze differences in patient and graft survival within different eras of surgical technique.

This study represents a retrospective analysis of all primary PT performed at the University Hospital Zurich between 1973 and 2023. According to differences in surgical technique, we defined five different eras of PT.

Overall, 280 primary PT were performed. Overall survival at 1, 5, and 10 years improved from 73.5%, 51%, 44.9% in Era 3, to 69.7%, 60.6%, 51.5% in Era 4, and 95.8%, 95.4%, 82.1% in Era 5, respectively (p < 0.001). Insulin‐free survival after 1, 5, and 10 years was 34.5%, 25.5%, 16.4% in Era 3, 41.5%, 34.1%, 31.7% in Era 4, and reached 85.5%, 78%, 64.5% in Era 5 (p < 0.001), respectively.

Enhanced surgical techniques and improvements in immunosuppression helped to overcome many obstacles that hampered the early days of PT, evolving PT into a safe and highly efficient procedure. PT represents the treatment of choice for patients with T1D and ESKD.

## Linked entities

- **Diseases:** type I diabetes mellitus (MONDO:0005147), end-stage kidney disease (MONDO:0004375)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** ESKD (MESH:D007676), T1D (MESH:D003922)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12588550/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12588550/full.md

## References

51 references — full list in the complete paper: https://tomesphere.com/paper/PMC12588550/full.md

---
Source: https://tomesphere.com/paper/PMC12588550